In a recently published trial of advanced bladder cancer, treatment with atezolizumab (anti-PD-L1 antibody) resulted in objective response rates of 26% (95% CI 18–36) in tumors with ≥ 5% PD-L1 expressing infiltrating immune cells [17]. Here, CD274 is linked to urinary bladder cancer.